Aim: Matrix metalloproteinase (MMP)-8, MMP-9, tissue inhibitor of matrix metalloproteinase (TIMP)-1 and myeloperoxidase (MPO) participate in extracellular matrix breakdown both in periodontium and atherosclerotic plaques. We investigated the diagnostic value of serum and saliva biomarkers in periodontitis and acute coronary syndrome (ACS).
| INTRODUC TI ON
In periodontitis and coronary heart disease (CHD), the extracellular matrix (ECM) breakdown represents a crucial factor in the pathophysiology. Firstly, matrix metalloproteinases (MMPs), especially MMP-8 and MMP-9, degrade ECM in periodontium and regulate remodelling processes in cardiovascular disease (CVD) that is atherosclerotic plaques. Secondly, the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) endogenously inhibits MMP-8 and MMP-9 (Visse & Nagase, 2003) , reflecting the balance of tissue destruction and protection (Gursoy et al., 2010) . Thirdly, myeloperoxidase (MPO) associates with inflammation (Leppilahti et al., 2014) , activating oxidatively latent MMP-8 and MMP-9 and inactivating TIMP-1 (Saari, Suomalainen, Lindy, Konttinen, & Sorsa, 1990) . MPO kills bacteria also by generating reactive oxygen species, that is hypochlorous acid (Strzepa, Pritchard, & Dittel, 2017) .
Saliva MMP-8, MMP-9 and MPO levels are elevated in patients having periodontitis , and saliva TIMP-1 is also important in periodontitis as being an inhibitor of MMPs (Gursoy et al., 2010) . Elevated serum MMP-8 (Marcaccini et al., 2009; Noack et al., 2017) and MMP-9 (Wick et al. 2013 ) concentrations have been found in periodontitis patients compared to healthy controls, but also opposite findings exist (Nizam et al., 2014) .
Elevated serum MMP-9 is associated with atherosclerosis and CVD (Yabluchanskiy, Ma, Iyer, Hall, & Lindsey, 2013) . Serum MMP-9 concentrations correlate with atherosclerotic plaque rupture (Fukuda et al., 2006) and myocardial tissue destruction (Newby 2016) . Furthermore, serum MMP-8 and TIMP-1 levels are associated with atherosclerotic plaque instability and acute coronary syndrome (ACS) (Pussinen et al., 2013) , predicting incident cardiovascular events (Tuomainen et al. 2014; Tuomainen et al., 2007) and especially fatal events (Tuomainen et al., 2007; Kormi et al. 2017 ).
Saliva biomarkers have also been investigated in CHD. An activated form of MMP-8 in saliva is significantly elevated in acute myocardial infarction (AMI) patients compared to non-AMI group, while total saliva MMP-8 concentrations were lower in AMI patients regardless of the oral status (Buduneli et al., 2011) . Elevated saliva MMP-8 concentrations have been associated with CHD in analyses where a number of teeth were taken into account as a sign of oral health (Furuholm et al., 2006) . After adjusting for periodontal status and smoking, saliva MMP-8 and MPO levels were significantly elevated among non-AMI subjects compared to AMI patients (Rathnayake et al., 2015) . In addition, biomarker concentrations may be affected by medications. For example, statin administration reduces significantly serum and plasma TIMP-1 (Ferretti, Bacchetti, Banach, Simental-Mendía, & Sahebkar, 2017; Tziakas et al., 2004) and MMP-9 levels (Andrade, do Valle, & Sandrim, 2013; Tziakas et al., 2004) , but concerning plasma MMP-9 also opposite findings exist (Ferretti et al., 2017) .
Biomarkers with more precise information additionally to clinical parameters in periodontitis and CVD are valuable to investigate. Due to similarities in pathophysiology of ECM breakdown in periodontitis and CHD giving an indication to the same biomarkers, our study aimed (a) to investigate and compare saliva and serum MMP-8, MMP-9, TIMP-1 and MPO concentrations in periodontitis and in ACS, (b) to evaluate the diagnostic value of these biomarkers, (c) to determine whether periodontitis and ACS confounds the diagnostics.
| MATERIAL S AND ME THODS

| Subjects and diagnosis
The study population consisted of PAROGENE patients, a subpopulation of the larger Corogene cohort (N = 5,809), described earlier in detail (Vaara et al., 2012) . PAROGENE (N = 508) included a cohort of randomly selected patients who underwent coronary angiography in Helsinki University Hospital and clinical oral and radiographic examination in University of Helsinki. PAROGENE cohort is described earlier more extensively (Buhlin et al., 2011) . Both saliva and serum samples were available for 481 subjects. Information about cardiovascular medications used before hospitalization and prescribed during hospitalization was collected.
The oral examination included periodontal probing pocket depth (PPD) measurements from six sites of the each tooth and bleeding on probing (BOP) registration (Buhlin et al., 2011) . Alveolar bone loss (ABL) was obtained from digital panoramic radiographs and calculated following way: no ABL, mild (ABL in cervical third of the root), moderate (ABL in the mid third of the root), severe (ABL in the apical third of the root), total ABL (Buhlin et al., 2011) . A patient was classified as having periodontitis if there was alveolar bone loss (mild to severe) and if PPD was ≥4 mm in ≥4 sites. Patients having no current periodontitis comprised periodontally healthy, gingivitis and edentulous patients.
A patient was diagnosed as having no coronary artery disease (CAD) (N = 115) if <50% stenosis of all coronary arteries was seen in
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angiography. Stable CAD (N = 175) diagnosis was set if >50% stenosis was detected in angiography. No CAD and stable CAD patients were merged as non-ACS group (N = 286) for further analysis to form a reference group for ACS patients. With this division, seizure CAD can be compared to more stable conditions. ACS patients (N = 163) had ≥50% stenosis in at least one coronary artery, episode of typical chest pain for ischaemia and elevated cardiac enzymes. "ACS-like, no significant CAD" patients were excluded from further analysis because of their low number (N = 28) and because of acute phase response related to takotsubo patients included in this group may be reflected in increases of inflammatory biomarker levels (Parkkonen et al. 2017 ).
The study was conducted according to the Declaration of 
| Laboratory determinations
Stimulated whole saliva samples were collected 37-224 days after angiography as described earlier (Hyvärinen et al., 2012) . The saliva was centrifuged for 3 min at 9,300 g, and the supernatants were 
| Statistics
The distribution of variables was tested before statistical analysis.
The normally distributed variables were presented as means and standard deviations (SDs). The statistical significance of the differences between the groups was tested by the independent samples t test. Categorical variables were tested by the chi-square test. The biomarker concentrations displayed skewed distributions and are presented as medians and interquartile ranges (IQRs). Statistical significance was tested using the Mann-Whitney test. The p-value for statistical significance was defined at 0.05.
Correlation coefficients were calculated using the Spearman's correlation. The diagnostic sensitivity and specificity of the biomarkers were calculated by receiver operating characteristics (ROC). The sensitivity and specificity are presented using the cut- Habibzadeh, & Yadollahie, 2016) . In the subgroups, the sensitivity was determined according to the specificity determined for the whole population.
Multivariate logistic regression models were used to determine the association of saliva biomarkers with periodontitis and serum biomarkers with ACS. The model was adjusted for age, sex, periodontitis or cardiac status, diabetes, and for use of statins (before or after hospitalization). The analyses were performed using IBM SPSS Statistics 22.
| RE SULTS
Characteristics of the subjects according to cardiac and periodontal status are presented in Table 1 . Patients in the non-ACS group had more often dyslipidemia compared to ACS patients. Periodontitis patients were more often older, diabetic, smokers, dyslipidemic and used more statins (Table 1) .
| Saliva biomarkers
Concentrations of saliva MMP-8, MMP-9, TIMP-1 and MPO differed significantly between periodontitis and non-periodontitis patients (Table 2) ; the MMP-8, MMP-9 and MPO were higher, and TIMP-1 concentrations lower in periodontitis. When these saliva biomarker concentrations were examined separately in different cardiac groups, similar significant trends according to periodontitis classification were observed. Only, the difference in saliva TIMP-1 turned to non-significant in non-ACS group (p = 0.109). There were no statistically significant differences according to coronary group in saliva MMP-8, MMP-9, TIMP-1 or MPO ( Table 2 ).
The diagnostic ability of biomarkers was investigated by ROC analysis. Saliva MMP-8, MMP-9 and MPO distinguished periodontitis patients from those without periodontitis with AUCs (p-value) 0.69 (<0.001), 0.66 (<0.001) and 0.68 (<0.001), respectively (Table 3 ).
Saliva TIMP-1 distinguished patients without periodontitis from those with periodontitis with AUC (p-value) 0.59 (0.001) ( Table 3) . Similar significant AUCs were observed, when the ROC analyses were performed separately in cardiac subgroups. Only saliva TIMP-1 did not distinguish periodontitis from non-periodontitis among the non-ACS patients (Table 3) .
Furthermore, saliva biomarkers were not useful in ACS diagnostics, except saliva TIMP-1 which distinguished ACS among patients without periodontitis, 0.64 (p = 0.005).
Using the ROC-curves, cut-off levels, sensitivity and specificity were determined for each biomarker (Table 3 ). The only notable difference in these analyses was that, when diagnosing periodontitis, the sensitivity of saliva MMP-9 and MPO was slightly better in ACS patients than in non-ACS patients.
The association of saliva biomarkers and covariates with periodontitis is shown in Table 4 . Saliva MMP-8, MMP-9, TIMP-1 and MPO concentrations had significant associations with periodontitis, the association of saliva TIMP-1 being inverse. Among all studied biomarkers, saliva MMP-8 had the strongest association with periodontitis with an OR (95% CI) of 4.07 (2.63-6.29), p < 0.001. The use of statins was significantly associated with periodontitis in all models. In addition, age associated with periodontitis in saliva MMP-8, MMP-9, and MPO models, and diabetes the saliva TIMP-1 model. 
| Serum biomarkers
Concentrations of serum MMP-8, MMP-9 and MPO were significantly higher in patients having ACS compared to non-ACS (Table 5 ).
When analysed in periodontitis patients only, the difference of serum MMP-9 between non-ACS and ACS lost its significance (Table 5) . Furthermore, the serum biomarker concentrations did not differ between patients with and without periodontitis (Table 5) .
Serum MMP-8, MMP-9or MPO provided significant AUCs (pvalue) for ACS: 0.73 (<0.001), 0.58 (0.04) and 0.68 (<0.001), respectively (Table 3) . Serum MMP-9 turned non-significant in periodontitis patients when diagnosing ACS (Table 3 ). Serum TIMP-1 did not distinguish ACS patients from non-ACS patients (Table 3 ). All AUC values of serum biomarkers regarding periodontal diagnosis were non-significant (data not shown). The sensitivity of serum MMP-8
for ACS diagnosis was slightly better in periodontitis compared to non-periodontitis patients. On the contrary, the sensitivity of serum MPO for ACS diagnosis was higher in non-periodontitis compared to periodontitis patients.
The associations of serum biomarkers with ACS are shown in 
| Biomarker correlations
The correlations between saliva and serum biomarker concentrations are presented in Table 7 . Saliva MMP-8 correlated significantly with saliva MMP-9, TIMP-1 and MPO. Furthermore, saliva MMP-9 had significant correlations with saliva TIMP-1 and TA B L E 3 ROC data describing the diagnostic ability of saliva and serum biomarkers in periodontitis and ACS 
| The effect of statins and diabetes
Serum biomarker concentrations were calculated according to significantly with periodontitis only in the saliva TIMP-1 model (Table 4) .
| D ISCUSS I ON
In this relatively large cohort of patients with detailed information of periodontal disease and coronary artery disease status, we found that saliva MMP-8, MMP-9, TIMP-1 and MPO levels associated significantly with periodontitis, while the corresponding serum concentrations associated with ACS. Some of the saliva biomarkers were confounded by the cardiac status, and some serum biomarkers were affected by the periodontal status. Saliva biomarkers had no diagnostic value in ACS, and serum biomarkers were not able to distinguish periodontitis patients from non-periodontitis.
We determined the cut-off values for all examined biomarkers according to the coordinate on the ROC curve with the minimum distance from the left-upper corner of the plot (Habibzadeh et al., 2016) . This approach results in a cut-off concentration, which produces the highest sensitivity and specificity at the same time and provides the most objective result. In the future studies or in the clinical practice, a more subjective approach could be used emphasizing either specificity or sensitivity after considering which is more important: the high proportion of true positive or the low proportion of false negative diagnosis. Considering periodontitis, it might be of interest to lower the threshold to identify truly healthy subjects from those requiring more periodontal counselling or treatment. Considering CAD, the biomarkers would be most valuable in differentiating ACS from other acute events with resembling clinical characters.
Serum MMP-8 and MPO were suitable for ACS diagnostic providing sensitivities of 65% and 64% and specificities 73% and 65%, respectively, with significant AUCs ranging between 0.68 and 0.73.
In the subgroup analyses, periodontal disease affected only slightly the sensitivities of these biomarkers in diagnosing ACS. The results of these subgroup analyses were confirmed in the whole population by logistic regression models, where periodontitis diagnosis as a confounder did not have a notable effect on the strong association between these biomarkers and ACS. Serum MMP-8 had the largest AUC values in ACS, while serum MPO had the highest odds for it.
Significant associations between circulating MMP-9 concentrations and ACS have been frequently reported in earlier studies by us and others (Derosa et al., 2007; Inokubo et al., 2001; Kai et al., 1998; Tan, Hua, Gao, & Fan, 2008; Tziakas et al., 2004 ) when compared to healthy controls. In the present population, serum MMP-9 associated significantly with ACS but the biomarker just weakly differentiated the patient groups from each other and the result was clearly affected by periodontal status. In the present study, serum TIMP-1 concentrations did not display significant AUC values in ACS diagnostics. The finding is different in relation to the earlier studies in other populations, in which serum or plasma TIMP-1 differentiated significantly ACS patients from healthy controls (Cavusoglu et al., 2006; Inokubo et al., 2001; Pussinen et al., 2013) . The low discrimination power of MMP-9 and TIMP-1 in the present study may be due to the reference group, non-ACS, which is composed of symptomatic patients indicated to coronary angiography (Buhlin et al., 2011) . However, the effect of periodontitis on the performance of these biomarkers in ACS diagnostics has not been taken into account in earlier studies, although elevated systemic levels of MMP-8 and MMP-9 have been observed in periodontitis patients (Marcaccini et al., 2009 ). The levels were reported to decrease after non-surgical periodontal therapy indicating both that periodontitis contributes to circulating MMP concentrations and that periodontitis plays a role in systemic inflammation (Marcaccini et al., 2009 ).
Among the measured saliva, biomarkers MMP-8, MMP-9 and MPO were almost equally powerful in detecting periodontitis. These differences were seen using medians, ROC analysis or logistic regression. Cardiac status had an effect on saliva MPO sensitivity in diagnosing periodontitis. Saliva MMP-8 had the highest AUC values in diagnosing periodontitis, and it also presented the highest odds for periodontitis. Similar results have been obtained in previous articles, where chronic periodontitis patients had significantly higher levels of MMP-8, MPO and activated MMP-9 in gingival crevicular fluid (GCF) compared to controls, and these levels decreased significantly three months after non-surgical periodontal therapy (Correa, Gonçalves, Figueredo, Gustafsson, & Orrico, 2008; Figueredo, Areas, Miranda, Fischer, & Gustafsson, 2004; Marcaccini et al., 2010) . Also saliva and GCF TIMP-1 have been utilized in periodontal diagnostics (Gursoy et al., 2010; Pozo et al., 2005) . Although in our study saliva TIMP-1 concentrations were significantly associated with periodontitis, the diagnostics was affected by the cardiac status.
MMP-8, MMP-9 and MPO correlated with each other when measured from the same sample material probably reflecting partially the same source of these molecules. Interestingly, serum and saliva biomarker levels did not correlate with each other indicating that the molecules are locally produced. At the same time, the result implies that these saliva biomarkers are not useful in the diagnostics of systemic conditions. Saliva diagnostics in medicine and pharmacotherapy is an area of vivid research to date (KaczorUrbanowicz et al., 2017) . Saliva biomarkers reflecting CVD are investigated abundantly (Miller et al., 2010) , because sampling of saliva is non-invasive, rapid and cost-effective (Miller et al., 2014) .
Saliva biomarkers such as, MMP-9, MPO, CRP, IL -1β, are presented to be promising in AMI diagnostics (Christodoulides et al., 2012) , and a panel of biomarker combinations in early stage of AMI is investigated (Floriano et al., 2009 ). However, challenges remain: saliva contains a lot of inhibitors and periodontitis-derived enzymes, which can disturb its use in diagnosing systemic diseases (Miller et al., 2010) .
It is known that many systemic disorders, medications, human habits and genetics can affect the biomarker levels. Serum MMP-8 concentrations are elevated in diabetic and hypercholesterolaemic patients, and statins reduce significantly serum MMP-8 and MMP-8/TIMP-1 ratio in these patients (Kadoglou, Sailer, Fotiadis, Kapelouzou, & Liapis, 2014) . In our study, statin users had lower serum MMP-8, MMP-9 and MPO compared to non-users, whereas diabetic subjects had higher saliva MMP-9, saliva MPO, serum TIMP-1 and serum MPO compared to non-diabetic patients.
Limitations of study include the cross-sectional, cohort setup.
We could not evaluate the prognostic value of these biomarkers with this study design. The biomarkers offering prognostic information would be important to explore, because, besides radiographs, the clinical oral and periodontal examinations are valuable in diagnosing the present and past periodontitis, but do not provide complete prediction of the future disease course (Miller et al., 2010) . Some evidence of the predictive value of MMP-8 in periodontitis progression exists (Leppilahti et al., 2015) . Multiple conditions that might affect the biomarker levels are not examined here. In addition to periodontally healthy patients, the non-periodontitis group comprised edentulous patients and those with gingivitis or history of periodontitis.
Edentulism, which can be regarded as a sign of past periodontitis, is associated with saliva biomarker levels (Palm et al., 2014; Salminen 2014) ; biomarkers deriving from the host may be even lower than those found in the healthy, when again bacterial biomarkers may be on the same level as in those with mild periodontitis. Our study population consisted of middle-aged and elderly subjects with an indication to coronary angiography and with multiple medications.
The non-ACS group included both patients with stable coronary artery disease and those without significant coronary artery disease.
Thus, the reference group has also medical concerns, which may be reflected in the results and diminish the differences observed. Taken together, the measured biomarkers most probably differentiate the groups with and without active tissue destruction.
Genetics play a role in periodontal and cardiovascular diseases and contribute directly to serum MMP-8 and MPO levels (Reiner et al., 2013; Salminen et al., 2017) . In meta-analysis, MMP-8 and MMP-9 polymorphisms were associated with periodontitis susceptibility (Weng et al., 2016) . Furthermore, the genetic variation in MMP-8 and MMP-9 genes is associated with risk for vascular diseases and CHD (Li et al., 2013; Pradhan-Palikhe et al., 2012) . To our knowledge, the input of heredity in salivary biomarker concentrations has not been studied.
MMP-8, MMP-9, TIMP-1 and MPO can be utilized as diagnostic aid of both periodontitis and ACS; saliva is useful for periodontal and serum for cardiac diagnostics. These biomarkers can be utilized by healthcare professionals in screening, and patients can be guided further to dentists or cardiologists. Periodontitis affects biomarker levels both locally in the oral cavity and systemically, and also acute coronary events are weakly reflected in saliva.
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